Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer

Background: Lipegfilgrastim (Lonquex®) has demonstrated to be non-inferior to pegfilgrastim (Neulasta®) in reducing the duration of severe neutropenia (SN) in patients with stage II−IV breast cancer. Compared to pegfilgrastim, lipegfilgrastim also demonstrated statistically significant lower time to...

Descripción completa

Detalles Bibliográficos
Autores principales: Akpo, Esse I. H., Jansen, Irshaad R., Maes, Edith, Simoens, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601405/
https://www.ncbi.nlm.nih.gov/pubmed/28955224
http://dx.doi.org/10.3389/fphar.2017.00614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601405/
https://www.ncbi.nlm.nih.gov/pubmed/28955224
http://dx.doi.org/10.3389/fphar.2017.00614

Ejemplares similares